Background Although skin diseases are often immediately visible to both patients and society, the morbidity they cause is only poorly defined. It has been suggested that quality-of-life measures may be a relevant surrogate measure of skin disease. Hidradenitis suppurativa (HS) leads to painful eruptions and malodorous discharge and is assumed to cause a significant degree of morbidity. The resulting impairment of life quality has not previously been quantitatively assessed, although such an assessment may form a pertinent measure of disease severity in HS. Objectives To measure the impairment of life quality in patients with HS. Methods In total, 160 patients suffering from HS were approached. The following data were gathered: quality-of-life data (Dermatology Life Quality Index, DLQI questionnaire), basic demographic data, age at onset of the condition and the average number of painful lesions per month. Results One hundred and fourteen patients participated in the study. The mean^SD age of the patients was 40´9^11´7 years, the mean^SD age at onset 21´8^9´9 years and the mean^SD duration of the disease 18´8^11´4 years. Patients had a mean^SD DLQI score of 8´9^8´3 points. The highest mean score out of the 10 DLQI questions was recorded for question 1, which measures the level of pain, soreness, stinging or itching (mean 1´55 points, median 2 points). Patients experienced a mean of 5´1 lesions per month. Conclusions HS causes a high degree of morbidity, with the highest scores obtained for the level of pain caused by the disease. The mean DLQI score for HS was higher than for previously studied skin diseases, and correlated with disease intensity as expressed by lesions per month. This suggests that the DLQI may be a relevant outcome measure in future therapeutic trials in HS.
Although skin diseases are often immediately visible the morbidity caused through them is only poorly defined. The lack of hard and easily quantifiable endpoints (e.g. death) makes objective measurements difficult. Furthermore, an individual's morbidity is influenced by a host of confounding factors, such as the symptoms caused by the condition, its visibility, the individual's coping ability and more. This problem is by no means unique to dermatology and many other specialities face similar problems. One approach to solving this issue has been the introduction of qualityof-life measures. Their use in the evaluation of the morbidity caused by skin diseases has been established over the past two decades. Reasons for such assessments include the demonstration of divergent opinions between doctors and patients on the relevance of a disease, 1, 2 to help in monitoring responses to treatment and judging the effectiveness of treatments, 3 and in helping health policy makers to weigh up the relative importance of different disease entities.
Hidradenitis suppurativa (HS) is a chronically relapsing skin disorder characterized by recurring inflammatory lesions in hair and apocrine glandbearing skin creases. The exact prevalence of HS is not known. In the U.K. its prevalence has been estimated at about 1 in 600 of the population, 4 while a Danish survey suggested a higher 1-year prevalence of 1´1% of the general population. 5 Although HS has been recognized for over 150 years the available treatments are on the whole only partially q 2001 British Association of Dermatologists effective and unsatisfactory. As the condition leads to painful eruptions and malodorous discharge it must be assumed that affected patients suffer a significant degree of morbidity. So far this impairment of life quality has never been quantitatively assessed.
In HS the need for a measurement of life quality impairment seems particularly significant. As a skin disease HS is subjected to the same prejudice as dermatological conditions in general, namely that they are generally harmless and merely`a mirror of the soul'. Furthermore, HS itself is poorly recognized by non-specialists and attracts only little research interest and publicity. Because HS predominantly affects intimate areas of the body the disease has the connotation of socially unacceptable behaviour or lack of hygiene and is often concealed even from close relatives. These factors in combination with the frequent lack of treatment efficacy suggest that the condition causes substantial morbidity for a large number of patients. The degree of morbidity suffered by these patients is currently unknown.
Materials and methods
Patients with an established diagnosis of HS were identified from databases of hospitals in Nottingham and Mansfield in the U.K. and Copenhagen and Roskilde in Denmark. Cases were traced back to 1993 in Nottingham, to 1995 in Mansfield and to 1997 in Roskilde. To be included as a case the diagnosis of HS had to be made by a fully trained dermatologist or had to be supported by histological evidence.
All patients received the Dermatology Life Quality Index (DLQI) questionnaire. 3 The questionnaire was chosen for its ease of use in a clinical setting, and because it has been widely used in other skin diseases. This allows a direct comparison of our results with those from previous studies. The DLQI is a 10-point questionnaire, developed by Professor A.Y.Finlay (Cardiff, U.K.), on the basis of patient interviews regarding the impact of their disease and its treatment. Scores obtained from healthy volunteers are significantly lower than those from dermatology patients and using a 1-week test±retest method the reliability has been found to be high. The U.K. patients received the original English language DLQI, while Danish patients received a previously translated Danish version.
In addition, all patients were asked about some basic demographic data and aspects of the history of their HS, either in a second questionnaire or during a standardized interview. Questions were asked about age at onset of the condition and about the average number of painful lesions per month. Non-responders were not analysed.
The main outcome measure was the mean DLQI score. In addition to presenting descriptive statistics on this cohort of patients, correlations between the descriptive variables and the DLQI scores were analysed using the rank Spearman test. Where appropriate, groups were compared using non-parametric statistics with Bonferroni's correction for multiple comparisons.
Results
One hundred and sixty patients were contacted, of whom 114 (71%) participated: 16 men and 98 women. Their mean^SD age was 40´9^11´7 years (range 20±76) and the self-reported mean^SD disease duration was 18´8^11´4 years (range 2±54). The self-reported mean^SD age at disease onset was 21´8^9´9 years. Nine patients indicated that they had not had any active disease within 1 year of our survey; the rest had had at least one painful HS lesion within the past 12 months.
The mean^SD DLQI score for the whole survey group was 8´9^8´3 points (range 0±29, median 7). This included 21 patients who scored zero. The highest mean score was recorded for question 1 (mean 1´55, Eighty-one patients gave details on the mean number of painful lesions suffered per month (Fig. 1) . The median number of lesions in this group was two per month. Because a handful of patients reported very frequent attacks (up to 30 per month) the mean number of self-reported HS lesions for the same group was 5´1 per month.
The DLQI score was independent of age or disease duration (Table 2 ). It did, however, correlate strongly with the number of lesions suffered per month (r 2 0´384). There was a negative correlation between the age at disease onset and DLQI (r 2 2 0´227). Age at onset correlated negatively with disease duration (r 2 2 0´411) and age correlated with duration of disease (r 2 0´675). Patients who scored 5 DLQI points or fewer (n 28) suffered a mean^SD of only 2´1^2´3 lesions per month. Those with 6±8 points on the DLQI scale (n 19) had a mean^SD of 6´0^6´7 lesions per month. Patients who scored 9 or more points (n 34) had a mean^SD of 6´7^7´7 lesions per month. The number of lesions varied significantly in the groups (P , 0´0006). The number of lesions per month for those with a DLQI score of up to 5 points was significantly lower than that of those with a score of 6±8 points or 9 or more points (both P , 0´01).
Discussion
Although many dermatologists rate HS as a`heart-sink condition' and would agree that it ranks among the most unpleasant skin diseases, the magnitude of disability caused by HS has remained unclear. Our study shows that HS patients seen in the secondary care setting suffer a high degree of morbidity. The recorded mean DLQI score of 8´9 is higher than scores found in several other dermatological conditions (see Table 3 ). The highest proportion of disability resulted from the soreness and pain created by the disease. Patients also suffered significant levels of embarrassment and self-consciousness. That patients felt handicapped by the perceived limitation in their choice of clothing may have its explanation in the frequent occurrence of boils with malodorous discharge and may also reflect the large female predominance in our study group.
The high degree of suffering endured by HS patients had hitherto neither been quantified nor sufficiently emphasized in the literature. So far only one study has shown impairment of self-reported health caused by DLQI, Dermatology Life Quality Index; *P , 0´05, **P , 0´01. HS, 5 but omitted to quantify it. In the same study Jemec et al. 5 found that patients with HS had lost an average of 2´7 days of work in 1 year. This ranked below the average number of work days lost for all reasons per employed person (7´5 days) and even more below the average number of days lost by patients with hand eczema (4 weeks) in a comparable population. In view of our results it may, therefore, be suggested that patients with HS fail to get appropriate recognition for the severity of their disease. Many of them seem to suffer in silence, as reflected in the name chosen by the HS self-help group`HIDE' (website: http:// webhome.globalserve.net.hidecan/). Failure to disclose the extent or even the existence of the disease may in itself increase its severity, as demonstrated in a study of acne patients. 6 In this study patients with facial acne were found to cope better with their disease than those affected by truncal acne. The authors suggested that in the absence of visible disease no support or sympathy is elicited and there is, therefore, no mitigation of suffering. The same mechanism may operate in HS, further compounded by the stigma attached to a condition affecting predominantly intimate body parts. Although such psychological factors are likely to aggravate the disease, the study of Jemec et al. 5 and also our own results make it clear that the most commonly cited reason for impaired health in HS patients is soreness or pain, both essentially physical disabilities. In some patients this can become severe enough to qualify the affected patient for a disability allowance.
The finding that the DLQI score is correlated with the number of active lesions offers the opportunity of using the DLQI as one tool in the measurement of disease activity. This could be of value in treatment studies, if used in combination with other appropriate instruments. Until now the most commonly used classification for the grading of HS is that proposed by Hurley. 7 This is, however, a physician-assessed clinical grading system, which describes long-term developments and is not sufficiently dynamic for the measurement of disease activity. Methods to record the severity of HS have been proposed by several authors, 8±12 but so far none has been validated.
The inverse correlation between DLQI score and age at disease onset supports our own suggestion that patients with late-onset disease tend to have an overall milder form of HS and a better chance of spontaneous recovery than those who develop the condition earlier in life. 13 This is in agreement with a previous observation on the outcome of simple surgical procedures in HS, where older patients appeared to have fewer recurrences. 14 The correlations between age, disease duration and age at onset are expected in a chronic disease.
The authors are aware that the study population is by definition the more severely affected group of HS sufferers and may therefore not be representative of all patients with this disease. Other weaknesses such as the recall element and the reliance on selfreported lesions also have to be acknowledged. The symptomatology of the disease is, however, easily recognized by the patients, and the study population is large enough to give a representative sample of the suffering among patients referred to the secondary care sector.
Our study underlines the importance of further research into HS. Of particular urgency seems to be the task of finding treatments that are able to provide more effective relief for patients with this distressing condition.
